Virtual Library

Start Your Search

S.K. Do



Author of

  • +

    Best abstracts selected from submissions 1 (ID 1)

    • Event: ACLC 2018
    • Type: Oral Session
    • Track:
    • Presentations: 1
    • +

      OA01 - LKB1 Pathway Variant TSC2 rs30259 Predicts the Prognosis in Early Stage Non-Small Cell Lung Cancer (ID 60)

      10:55 - 11:30  |  Author(s): S.K. Do

      • Abstract

      Background:
      This study was conducted to investigate the associations between polymorphisms of genes involved in LKB1 pathway and the prognosis of patients with non-small cell lung cancer (NSCLC) after surgical resection.


      Method:
      Twenty-three single nucleotide polymorphisms (SNPs) in LKB1 pathway were investigated in a total of 782 patients with NSCLC who underwent curative surgery. The association of the SNPs with overall survival (OS) and disease free survival (DFS) were analyzed.


      Results:
      Among the 23 SNPs investigated, TSC2 rs30259G>A was significantly associated with survival outcomes in multivariate analyses. The TSC2 rs30259G>A was associated with significantly worse OS and DFS (adjusted hazard ratio [aHR] = 1.88, 95% confidence interval [CI] = 1.21-2.91, P = 0.005; aHR = 1.65, 95% CI = 1.15-2.38, P = 0.01, under codominant model, respectively). When stratified by tumor histology, the SNP (rs30259) was significantly associated with survival outcomes only in squamous cell carcinoma, but not in adenocarcinoma. List of analyzed SNPs and the association with survival outcomes. Pa for Overall survival Pa for Disease-free survival SNP ID Gene Base change MAF Dominant Recessive Codominant Dominant Recessive Codominant rs30259 TSC2 G>A 0.04 0.01 0.15 0.005 0.03 8 x 10-6 0.01 rs1130214 Akt1 G>T 0.13 0.90 0.65 0.94 0.23 0.65 0.35 rs2494750 Akt1 A>G 0.38 0.33 0.88 0.61 0.33 0.56 0.36 rs17036508 MTOR T>C 0.12 0.36 0.97 0.20 0.72 0.71 0.82 rs1135172 MTOR C>T 0.16 0.48 0.98 0.60 0.22 0.51 0.29 rs1034528 MTOR G>C 0.19 0.81 0.35 0.75 0.40 0.99 0.41 rs1057079 MTOR A>G 0.18 0.90 0.34 0.79 0.19 0.97 0.29 rs3765904 MTOR T>C 0.01 0.32 . 0.46 0.33 . 0.46 rs11121691 MTOR C>T 0.07 0.97 0.98 0.86 0.87 0.98 0.73 rs7711806 PRKAA1 T>C 0.24 0.50 0.99 0.57 0.24 0.85 0.30 rs1342382 PRKAA2 A>T 0.25 0.93 0.17 0.73 0.32 0.20 0.68 rs11581010 PRKAA2 A>G 0.11 0.88 0.98 0.72 0.66 0.96 0.54 rs857148 PRKAA2 G>T 0.42 0.94 0.99 0.85 0.81 0.96 0.82 rs9803799 PRKAA2 T>G 0.16 0.54 0.23 0.98 0.43 0.71 0.63 rs4912411 PRKAA2 C>A 0.38 0.39 0.25 0.25 0.47 0.06 0.18 rs3738568 PRKAA2 T>C 0.36 0.31 0.50 0.35 0.26 0.28 0.21 rs739441 TSC1 A>G 0.26 0.12 0.31 0.16 0.56 0.45 0.48 rs1050700 TSC1 A>G 0.25 0.14 0.77 0.14 0.62 0.84 0.70 rs2809244 TSC1 C>A 0.39 0.47 0.49 0.31 0.62 0.99 0.66 rs4962225 TSC1 A>C 0.12 0.76 0.24 0.45 0.66 0.56 0.54 rs2074969 TSC2 G>C 0.22 0.92 0.09 0.60 0.96 0.17 0.59 rs3806317 PRKAA2 C>T 0.12 0.71 0.51 0.37 0.50 0.48 0.32 rs701848 PTEN C>T 0.47 0.55 0.89 0.63 0.51 0.77 0.68 MAF, minor allele frequency a P-values calculated using multivariate Cox proportional hazard models, adjusted for age, gender, smoking status, tumor histology, pathologic stage, and adjuvant therapy.


      Conclusion:
      This study suggests that genetic variation in LKB1 pathway may be useful for the prediction of prognosis in patients with early stage NSCLC after curative surgery.